Clearmind submits psychedelic therapy recommendations to FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Clearmind submits psychedelic therapy recommendations to FDA
October 7, 2026 8:40 AM EDT
Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder
Vancouver, Canada, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the Company), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (AUD), today announced that it has submitted recommendations to the U.S. Food and Drug Administration (FDA) in response to the agencys public hearing and request for comments on Considerations for Potential Future Therapeutic Use of Psychedelic Drugs.
Under FDA Docket No.... More
